Balance Sheet
Cash Flow Statement
Daily Values
DMA 100DMA 200DMA 50Dividend YieldEV to CFOEV to EBITEV to EBITDAEV to FCFEV to RevenueEnterprise ValueMarket Cap to FCFMarket CapitalizationPricePrice to EarningsPrice to Sales
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Allarity Therapeutics (ALLR) Enterprise Value (2024 - 2025)

Allarity Therapeutics' Enterprise Value history spans 2 years, with the latest figure at -$14.8 million for Q4 2025.

  • For Q4 2025, Enterprise Value fell 20413.89% year-over-year to -$14.8 million; the TTM value through Dec 2025 reached -$14.8 million, down 20413.89%, while the annual FY2025 figure was -$14.8 million, 20413.89% down from the prior year.
  • Enterprise Value reached -$14.8 million in Q4 2025 per ALLR's latest filing, down from -$2.5 million in the prior quarter.
  • In the past five years, Enterprise Value ranged from a high of -$72000.0 in Q4 2024 to a low of -$19.2 million in Q2 2024.